Graft vs Host Disease

"Graft vs Host Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.

Descriptor ID	D006086
MeSH Number(s)	C20.452
Concept/Terms	Graft vs Host Disease Graft vs Host Disease Graft-Versus-Host Disease Disease, Graft-Versus-Host Diseases, Graft-Versus-Host Graft Versus Host Disease Graft-Versus-Host Diseases Runt Disease Disease, Runt Graft-vs-Host Disease Disease, Graft-vs-Host Diseases, Graft-vs-Host Graft-vs-Host Diseases Homologous Wasting Disease Disease, Homologous Wasting

Below are MeSH descriptors whose meaning is more general than "Graft vs Host Disease".

Below are MeSH descriptors whose meaning is related to "Graft vs Host Disease".

Below are MeSH descriptors whose meaning is more specific than "Graft vs Host Disease".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Graft vs Host Disease" by people in this website by year, and whether "Graft vs Host Disease" was a major or minor topic of these publications.

Bar chart showing 77 publications over 24 distinct years, with a maximum of 9 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1999	2	0	2
2000	1	1	2
2003	4	1	5
2004	0	1	1
2005	1	0	1
2006	0	1	1
2008	1	1	2
2009	3	0	3
2010	1	2	3
2011	1	0	1
2013	2	0	2
2014	4	0	4
2015	1	2	3
2016	2	3	5
2017	1	3	4
2018	2	1	3
2019	7	0	7
2020	4	3	7
2021	3	0	3
2022	9	0	9
2023	5	0	5
2024	2	0	2
2025	1	0	1

Below are the most recent publications written about "Graft vs Host Disease" by people in Profiles.

Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, Askar M, Petersdorf E, Ringden O, Kanakry CG, Kanakry JA, Stefanski H, Arrieta-Bola?os E, Betts B, Benjamin C, Gadalla S, Wang T, Saultz J, Spellman S, Jurdi NE, Bolon YT, Lee SJ. Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations. Transplant Cell Ther. 2025 Sep; 31(9):680-692.

View in: PubMed
Grunwald MR, Sha W, He J, Sanikommu S, Gerber JM, Ai J, Knight TG, Fasan O, Boseman V, Kaizen W, Chojecki A, Ragon BK, Symanowski J, Avalos B, Copelan E, Ghosh N. Biologically Randomized Comparison of Haploidentical Versus Human Leukocyte Antigen-Matched Related Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 12; 30(12):1211.e1-1211.e11.

View in: PubMed
Lahijani S, Rueda-Lara M, McAndrew N, Nelson AM, Guo M, Knight JM, Wiener L, Miran DM, Gray TF, Keane EP, Yek MH, Sannes TS, Applebaum AJ, Fank P, Babu P, Pozo-Kaderman C, Amonoo HL. A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease. Transplant Cell Ther. 2024 09; 30(9S):S493-S512.

View in: PubMed
Kalinina O, Minter LM, Sperling AI, Hollinger MK, Le P, Osborne BA, Zhang S, Stiff P, Knight KL. Exopolysaccharide-Treated Dendritic Cells Effectively Ameliorate Acute Graft-versus-Host Disease. Transplant Cell Ther. 2024 01; 30(1):79.e1-79.e10.

View in: PubMed
Ustun C, Chen M, Kim S, Auletta JJ, Batista MV, Battiwalla M, Cerny J, Gowda L, Hill JA, Liu H, Munshi PN, Nathan S, Seftel MD, Wingard JR, Chemaly RF, Dandoy CE, Perales MA, Riches M, Papanicolaou GA. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 01; 59(1):76-84.

View in: PubMed
Htut M, Dhakal B, Cohen AD, Martin T, Berdeja JG, Usmani SZ, Agha M, Jackson CC, Madduri D, Deraedt W, Zudaire E, Yeh TM, Xu X, Pacaud L, Akram M, Jagannath S. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 12; 23(12):882-888.

View in: PubMed
Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ort? G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 07 01; 108(7):1900-1908.

View in: PubMed
Koshy AG, Kim HT, Liegel J, Arnason J, Ho VT, Antin JH, Joyce R, Cutler C, Gooptu M, Nikiforow S, Logan EK, Elavalakanar P, Narcis M, Stroopinsky D, Avigan ZM, Boussi L, Stephenson S, El Banna H, Bindal P, Cheloni G, Avigan DE, Soiffer RJ, Rosenblatt J. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023 06 15; 141(24):2932-2943.

View in: PubMed
Ramanathan M, Kim S, He N, Chen M, Hematti P, Abid MB, Rotz SJ, Williams KM, Lazarus HM, Wirk B, Yin DE, Kanakry CG, Perales MA, Chemaly RF, Dandoy CE, Riches M, Ustun C. The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study. Bone Marrow Transplant. 2023 04; 58(4):360-366.

View in: PubMed
Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, Eduru SK, Buschke S, Lang B, Liesenfeld KH, Schaible J, McCabe D. Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial. Am J Clin Dermatol. 2022 Sep; 23(5):719-728.

View in: PubMed

People

Explore

Similar Concepts

Top Journals